Completed
PHASE2
INTERVENTIONAL
NCT01280344
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Interventions
Name:
Saline Solution for Injection
Type:
DRUG
Description:
Intravenous (IV)
Name:
Ipamorelin
Type:
DRUG
Description:
Intravenous (IV)
Primary Outcomes
Measure:
Recovery of Gastrointestinal (GI) Function
TimeFrame:
Up to 10 days
Description:
To assess the efficacy of three repeated dose levels of ipamorelin vs. placebo
Trial Information
NCT ID
NCT01280344
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Helsinn Therapeutics (U.S.), Inc
Last Updated
December 15, 2025